about
WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancerPhosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell linesExpression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patientsStructural analysis of the catalytically inactive kinase domain of the human EGF receptor 3Treatment of vestibular schwannoma cells with ErbB inhibitorsEmerging therapies in gastrointestinal cancers.ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancerThe epidermal growth factor receptor family in breast cancer.Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4Glycosyltransferases as Markers for Early Tumorigenesis.Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsPTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy.Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.Potential of ErbB4 antibodies for cancer therapy.Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.The role of ADAM17 in tumorigenesis and progression of breast cancer.ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains.The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056Gene expression profiling of ErbB receptor and ligand-dependent transcription.Prognostic value of ERBB family mRNA expression in breast carcinomas.Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study.Significance of epidermal growth factor receptor expression in breast cancer.Gene expression profiling of ErbB receptors and ligands in human meningiomas.Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome.Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer.EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
P2860
Q24309041-C64E8942-E61F-41B1-9C2C-7926922CC4C0Q24318725-6EEC249C-559D-45B3-BC0C-4C0C36215BFBQ24645597-826CF9DC-CD1E-42C7-9A68-E4B4CEC5F774Q27646596-BE88A25D-8857-4F07-A4BD-51C7E3B175AFQ30458767-306BFC13-8014-4A81-9FF1-9D34F2915E54Q33866870-F15B16BB-1C09-407C-9AD6-C91D0DD4DF4CQ33921374-482F8756-9CBA-4D6B-90CC-49D1FEF4E7E7Q34363400-80827B3D-C0F6-4ECC-8C1B-FFCD34E4FF5FQ34428742-294D3AD4-88D1-4EAA-AACC-2AD92FF9A0CEQ34496697-46F074F8-E521-4877-A557-31BAAC0784C6Q35012797-3FD0EE5C-0907-4725-BD5C-70BF4BE2FA4CQ35586732-50687041-BEC0-4ECB-98AD-A63B0DCBD404Q35802482-93DDC6FE-13CB-4BB3-AE49-759BCEE5757FQ36080448-9865395C-49D9-42E8-BD2A-DD4010E8B1BAQ36396421-C0FC66D5-DA14-4F08-9578-DC7BA9BE004EQ36609982-D274E590-1110-43F8-92FF-C0B52E15731CQ36622264-F12397CA-133B-419C-9C9C-47F6970A977AQ36677496-67C8A237-B6E6-4F9D-9054-CBBE78D12F76Q36696088-86BF125F-8F7B-4ED3-9806-C0F5D7A21729Q36742363-089023E1-7B6E-4D98-8B37-BB9A01EE6D47Q37289310-64E65FFA-49C9-48A2-BA71-BA05761A1AD6Q37373606-01F808D9-CB6F-4771-8885-2EDB41006925Q37413628-A53782D4-7268-45A2-BDFE-ECB19681083FQ37658764-EA278105-B59D-4BF1-B9AA-0FB64061F8EDQ37727542-A0FE98AF-EF02-4297-B8BB-C8DBE0A6C95CQ38961857-60A7E93C-516E-4E8B-B1E9-F018EA5D63C0Q39136071-761506A8-8B30-4FDF-A51B-20005C84A12BQ39406282-709440D5-6B9E-4A60-9E59-D3E897BD47C9Q40587910-4E288255-AAD2-4D82-94C7-2F8CC8043AB2Q43461671-68EE18D9-DE07-40A3-A498-BEA31D9076BCQ43754966-917C44E4-FD67-4997-A59E-0AB5A876599AQ45234395-272F599B-947C-43D2-AA6B-C182F843F8A8Q45885250-43306E0C-B3B2-4761-9583-48A6ECD1C771Q47135806-1DB22DF5-7AC0-4CE7-9184-F01BEA790ED2Q52676608-777BECD8-58D8-44B3-AAD2-65B9754B32C6Q53810400-37740140-8272-44D3-B7DF-FD1FD38D7EF2
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
c-erbB-4 protein expression in human breast cancer
@ast
c-erbB-4 protein expression in human breast cancer
@en
type
label
c-erbB-4 protein expression in human breast cancer
@ast
c-erbB-4 protein expression in human breast cancer
@en
prefLabel
c-erbB-4 protein expression in human breast cancer
@ast
c-erbB-4 protein expression in human breast cancer
@en
P2093
P2860
P356
P1476
c-erbB-4 protein expression in human breast cancer
@en
P2093
Gullick WJ
Nicholson RI
Srinivasan R
P2860
P2888
P304
P356
10.1054/BJOC.1999.1057
P407
P577
2000-03-01T00:00:00Z
P5875
P6179
1034062010